| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2399 from our risk checks.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥10.36 |
| 52 Week High | CN¥12.97 |
| 52 Week Low | CN¥6.89 |
| Beta | 0.47 |
| 1 Month Change | 19.63% |
| 3 Month Change | 35.78% |
| 1 Year Change | -17.45% |
| 3 Year Change | -35.81% |
| 5 Year Change | -51.36% |
| Change since IPO | -81.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2399 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 12.7% | 5.6% | 3.1% |
| 1Y | -17.5% | -11.0% | -13.1% |
Return vs Industry: 002399 underperformed the CN Pharmaceuticals industry which returned -11% over the past year.
Return vs Market: 002399 underperformed the CN Market which returned -13.1% over the past year.
Price Volatility
| 2399 volatility | |
|---|---|
| 2399 Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 002399's share price has been volatile over the past 3 months.
Volatility Over Time: 002399's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 2,080 | Yu Shan | www.hepalink.com |
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 2399 fundamental statistics | |
|---|---|
| Market cap | CN¥13.61b |
| Earnings (TTM) | -CN¥694.76m |
| Revenue (TTM) | CN¥5.52b |
2.8x
P/S Ratio-21.9x
P/E RatioIs 2399 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2399 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.52b |
| Cost of Revenue | CN¥4.55b |
| Gross Profit | CN¥964.60m |
| Other Expenses | CN¥1.66b |
| Earnings | -CN¥694.76m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 17.48% |
| Net Profit Margin | -12.59% |
| Debt/Equity Ratio | 40.0% |
How did 2399 perform over the long term?
See historical performance and comparison